Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
Portfolio Pulse from
Acadia Pharmaceuticals reported mixed Q4 results with earnings missing estimates but revenues exceeding them, driven by growth in Nuplazid and Daybue sales.
March 04, 2025 | 10:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Acadia Pharmaceuticals' Q4 earnings missed estimates, but revenues beat expectations due to strong sales of Nuplazid and Daybue.
The mixed results with earnings missing but revenues beating expectations suggest a neutral short-term impact. The strong sales of Nuplazid and Daybue are positive, but the earnings miss tempers enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100